RESERPINE SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C33H40N2O9.H2O4S
Molecular Weight	706.7596
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COc1ccc2c3CCN4C[C@@]5([H])C[C@]([H])([C@@]([H])([C@]([H])([C@@]5([H])C[C@]4([H])c3[nH]c2c1)C(=O)OC)OC)OC(=O)c6cc(c(c(c6)OC)OC)OC.OS(=O)(=O)O

InChI

InChIKey=FAXJAGWYPFUKMP-BQTSRIDJSA-N

InChI=1S/C33H40N2O9.H2O4S/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19;1-5(2,3)4/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3;(H2,1,2,3,4)/t18-,22+,24-,27-,28+,31+;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C33H40N2O9
Molecular Weight	608.68
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O4S
Molecular Weight	98.0796
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | https://www.ncbi.nlm.nih.gov/pubmed/15529229 | https://www.ncbi.nlm.nih.gov/pubmed/23831411

Reserpine is an alkaloid, isolated from the Rauwolfia serpentina plant and developed by Ciba pharma. Reserpine was approved by FDA for the treatment of hypertension and psychotic disorders. The drug exerts its effect by blocking two vesicular monoamine transporters, VMAT1 and VMAT2. The blockade results in vesicles that lose their ability to store neurotransmitter molecules. Neurotransmitters, thus retained in cytosol, are then neutralized by MAO.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vesicular amine transporter 1 6 Target ID: CHEMBL1838 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23831411	Blocker 506		160.0 nM [IC50]
Synaptic vesicular amine transporter 49 Target ID: CHEMBL1893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23831411	Blocker 506		350.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 513 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462	Primary		Approved 8003	RESERPINE Approved Use Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication. Launch Date -4.66300797E11
Agitated psychotic states 6 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462	Palliative		Approved 8003	RESERPINE Approved Use Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication. Launch Date -4.66300797E11

C_max

Value	Dose	Co-administered	Analyte	Population
0.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30465727	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Equus caballus population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
4.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30465727	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Equus caballus population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
23.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30465727	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Equus caballus population: HEALTHY age: ADULT sex: MALE food status: FED

Doses

Dose	Population	Adverse events
0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	Disc. AE: Drowsiness, Light headedness... AEs leading to discontinuation/dose reduction: Drowsiness (1 patient) Light headedness (light, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	Disc. AE: Upper abdominal pain, Postural hypotension... AEs leading to discontinuation/dose reduction: Upper abdominal pain (1 patient) Postural hypotension (1 patient) Electrocardiogram abnormal (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17628352

AEs

AE	Significance	Dose	Population
Drowsiness	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Light headedness	light, 1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Electrocardiogram abnormal	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Postural hypotension	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Upper abdominal pain	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1461 activator 74	inhibitor 1605	inhibitor 1701	inhibitor 1480

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1344 BSEP 378 BCRP 654 MRP2 349 OATP1B1 741 OATP1B3 657 OATP2B1 109 CYP1A2 1386 CYP2C19 1324 CYP2A6 621 CYP2E1 785 Kv1.3 16 MRP3 151 MRP4 197	P-gp 1399	P-gp 247 CYP3A4/5 108

Drug as perpetrator

Target	Modality	Activity
CYP3A4 1768	activator 200 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNzcyIn19	no [Activation >3.9811 uM]
CYP2A6 653	inhibitor 3041 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 866	inhibitor 3041 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP1A2 1532	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	no
CYP2C9 1652	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	no
OATP1B3 666	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	unlikely [Inhibition 20 uM]
MRP3 209	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	weak [IC50 133 uM]
MRP4 229	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	weak [IC50 133 uM]
Kv1.3 31	inhibitor 3041 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X11000706	weak [IC50 58 uM]
BSEP 379	inhibitor 3041 Sources: http://transportal.compbio.ucsf.edu/compounds/reserpine/, https://pubmed.ncbi.nlm.nih.gov/19520776/	yes [IC50 2.8 uM]
CYP3A4 1768	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/11743742/, https://pubmed.ncbi.nlm.nih.gov/24396142/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNzcyIn19	yes [IC50 20.4 uM]
BCRP 723	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/31571164/, https://pubmed.ncbi.nlm.nih.gov/17430633/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50017712, https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 26.3 uM]
CYP2C19 1394	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	yes [IC50 <0.03 uM]
CYP2D6 1735	inhibitor 3041 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	yes [IC50 <0.2 uM]
OATP1B1 756	inhibitor 3041 Sources: https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/22541068/	yes [Inhibition 20 uM]
OATP2B1 112	inhibitor 3041 Sources: https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/22541068/	yes [Inhibition 20 uM]
P-gp 1519	inhibitor 3041 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/10080959/, http://transportal.compbio.ucsf.edu/compounds/reserpine/, https://pubmed.ncbi.nlm.nih.gov/12134945/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	yes [Ki 1.38 uM]
MRP2 436	inhibitor 3041 Sources: http://transportal.compbio.ucsf.edu/compounds/reserpine/,https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/12134946/, https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.genome.jp/kegg/drug/br08309.html, https://pubmed.ncbi.nlm.nih.gov/18457386/	yes [Ki 295 uM]
CYP3A4/5 292	inducer 1443 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/8632764/	yes
P-gp 1519	inducer 1443 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/8632764/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1399	substrate 3107 Sources: https://pubmed.ncbi.nlm.nih.gov/31571164/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1512	inhibitor 1494 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X11000706

PubMed

Title	Date	PubMed
The effect of 5-hydroxytrytamine synthesis inhibitors on neuroleptic-induced catalepsy in rats.	1975	1172422
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?	1999	10651103
Reserpine modulates serotonin transporter mRNA levels in the rat brain.	1999	10027743
Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.	2000 Mar	10683491
Role of prolactin in chloro-S-triazine rat mammary tumorigenesis.	2000 Nov	11071396
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.	2001 Aug	11400182
Trends in antihypertensive drug use among orally treated diabetic patients, in France between 1981 and 1992. Impact of guidelines and new drugs.	2001 Dec	11852374
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.	2001 Feb 13	11172060
Determination of vitamin B(6) in cooked sausages.	2001 Jan	11170557
Separation of the insecticidal pyrethrin esters by capillary electrochromatography.	2001 Jan 5	11206800
Liquid chromatographic method with electrochemical detection for determination of cisapride in serum.	2001 Jan-Feb	11234857
Analysis of phenolic constituents of biological interest in red wines by high-performance liquid chromatography.	2001 Jul 13	11486883
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.	2001 Jun	11358453
[Recognition and quantitative contrast characteristic components for root of Chinese angelica].	2001 Mar	12541663
[Determination of bifonazole in cream by high performance liquid chromatography].	2001 May	12541819
[Study of diphacinone in biological samples by high performance liquid chromatography/diode array detector].	2001 May	12541808
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.	2001 May	11318962
[Determination of nitidine in different parts of Zanthoxylum nitidum].	2001 Sep	11799776
Identification of mammary carcinogens in rodent bioassays.	2002	11921183
Heterologous expression of a Rauvolfia cDNA encoding strictosidine glucosidase, a biosynthetic key to over 2000 monoterpenoid indole alkaloids.	2002 Apr	11985599
Temperature effect on peak width and column efficiency in subcritical water chromatography.	2002 Feb	11881703
Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography.	2002 Feb 5	11863286
Development and validation of a reversed-phase high-performance liquid chromatographic method for the determination of ethyl-3-(N-n-butyl-N-acetyl)aminopropionate in an insect repellent semi-solid formulation.	2002 Feb 8	11873978
[Application of fingerprint chromatogram in quality control of Shen-Mai injection].	2002 Jul	12541909
Increase of free cysteine and citric acid in plant cells exposed to cobalt ions.	2002 Jul	12052512
Validated HPLC method for determination of sennosides A and B in senna tablets.	2002 Jul 31	12093522
Rapid high-performance liquid chromatographic assay of dorzolamide in rabbit aqueous humor.	2002 Jun	11933028
Determination of ethylenediamine tetraacetic acid in injection forms by ion-pair chromatography.	2002 Jun 15	12049972
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].	2002 May	12774329
LC-MS/MS determination of a farnesyl transferase inhibitor in human plasma and urine.	2002 Nov 7	12408906
Determination of undecylenic and sorbic acids in cosmetic preparations by high performance liquid chromatography with electrochemical detection.	2002 Nov 7	12408884
The physiology of overwintering in a turtle that occupies multiple habitats, the common snapping turtle (Chelydra serpentina).	2002 Sep-Oct	12529844
Determination of peptides and amino acids from wool and beer with sensitive fluorescent reagent 2-(9-carbazole)-ethyl chloroformate by reverse phase high-performance liquid chromotography and liquid chromotography mass spectrometry.	2003 Feb 1	12576053
DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.	2003 Feb 24	12592376
Analysis of selected withanolides in plant extract by capillary electrochromatography and microemulsion electrokinetic chromatography.	2003 Jan	12569525
Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line.	2003 Jan 14	12525265
Analysis of flecainide and two metabolites in biological specimens by HPLC: application to a fatal intoxication.	2003 Jan-Feb	12587684
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.	2003 Jun	12711835
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.	2003 May 21	12748199

Patents

Sample Use Guides

In Vivo Use Guide

Hypertension: In the average patient not receiving other antihypertensive agents, the usual initial dosage is 0.5 mg daily for 1 or 2 weeks. For maintenance, reduce to 0.1-0.25 mg daily. Psychiatric Disorders: the usual initial dosage is 0.5 mg daily, but may range from 0.1 mg to 1.0 mg. Adjust dosage upward or downward according to the patient's response.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Jun 26 13:45:34 UTC 2021` Edited by `admin` on `Sat Jun 26 13:45:34 UTC 2021`
Record UNII	KM25ND9T2H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RESERPINE SULFATE

Common Name

English

YOHIMBAN-16-CARBOXYLIC ACID, 11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)-, METHYL ESTER, (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-, SULFATE (1:1)

Systematic Name

English

3.BETA.,20.ALPHA.-YOHIMBAN-16.BETA.-CARBOXYLIC ACID, 18.BETA.-HYDROXY-11,17.ALPHA.-DIMETHOXY-, METHYL ESTER, 3,4,5-TRIMETHOXYBENZOATE (ESTER), SULFATE (1:1)

Systematic Name

English

Code System Code Type Description

FDA UNII

KM25ND9T2H

Created by admin on Sat Jun 26 13:45:35 UTC 2021 , Edited by admin on Sat Jun 26 13:45:35 UTC 2021

PRIMARY

CAS

6105-95-9

Created by admin on Sat Jun 26 13:45:35 UTC 2021 , Edited by admin on Sat Jun 26 13:45:35 UTC 2021

PRIMARY

PUBCHEM

133082397

Created by admin on Sat Jun 26 13:45:35 UTC 2021 , Edited by admin on Sat Jun 26 13:45:35 UTC 2021

PRIMARY

Related Record Type Details


					8B1QWR724A

RESERPINE

PARENT -> SALT/SOLVATE

Details

SMILES

InChI

DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | https://www.ncbi.nlm.nih.gov/pubmed/15529229 | https://www.ncbi.nlm.nih.gov/pubmed/23831411

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Patents

Sample Use Guides

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | https://www.ncbi.nlm.nih.gov/pubmed/15529229 | https://www.ncbi.nlm.nih.gov/pubmed/23831411

C_max

T_1/2

Drug as perpetrator